Avibactam Sodium/Ceftazidime

阿维巴坦钠/头孢他啶

Report date: 2026/05/20 20:02:01
QIDP

Base Information

Drug NameAvibactam Sodium/Ceftazidime
Drug Alias Name头孢他啶和阿维巴坦钠Ceftazidime and Avibactam Sodium头孢他啶/阿维巴坦Ceftazidime-Avibactam SodiumAvibactam Sodium and Ceftazidime +[15] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics
Mechanisms of ActionCell wall inhibitorsBacterial penicillin-binding protein inhibitorsBeta Lactamase inhibitors
TargetsBacterial penicillin-binding proteinBeta Lactamase
Therapy Area/IndicationsHospital-acquired pneumoniaSystemic Inflammatory Response SyndromeCystitis +[14] 
Global Approved IndicationsHospital-acquired pneumoniaCystitisPyelonephritis +[12] 
Approved Indications in ChinaHospital-acquired pneumoniaIntraabdominal InfectionsPneumonia, Ventilator-Associated
Original Approved Country/TerritoryUnited States
Original Approved Date2015/02/25
Country/TerritoryCzechiaBulgariaUnited States +[43] 
CombinationsYes Ceftazidime
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAllergan PlcPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Ireland Pharmaceuticals LtdPfizer Japan IncAbbvie Inc
Inactive CompaniesAstrazeneca Pharmaceutical Co LtdAstrazeneca Uk LtdGlaxosmithkline Manufacturing Spa +[8] 
Active IndicationsHospital-acquired pneumoniaCystitisPyelonephritis +[12] 
Inactive IndicationsSystemic Inflammatory Response SyndromeHealthcare-Associated Pneumonia

Other Information

ATC CodeJ01DD52
Related LinksWikipediaKEGG